Selected research
Industry Research
Gastric Mucosal Protective Drugs Industry Research Report 2026
Market perspective
The global Gastric Mucosal Protective Drugs market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Gastric Mucosal Protective Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Gastric Mucosal Protective Drugs is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Gastric Mucosal Protective Drugs is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Gastric Mucosal Protective Drugs include Abbott, Takeda Pharmaceutical, Taiho Pharmaceutical, Sucralfate (Carafate), Pharmaking, Misoprostol (Cytotec), Eisai, Daewoong Pharmaceutical and Cadila Healthcare, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Gastric Mucosal Protective Drugs market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Gastric Mucosal Protective Drugs Market by Company
Abbott
Takeda Pharmaceutical
Taiho Pharmaceutical
Sucralfate (Carafate)
Pharmaking
Misoprostol (Cytotec)
Eisai
Daewoong Pharmaceutical
Cadila Healthcare
Bismuth Subsalicylate (Pepto-Bismol)
AstraZeneca
Gastric Mucosal Protective Drugs Segment by Type
Oral Medicines
Injectable Medicines
Gastric Mucosal Protective Drugs Segment by Application
Child patients
Elderly patients
Youth patients
Infant patients
Gastric Mucosal Protective Drugs Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Colombia
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Gastric Mucosal Protective Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Gastric Mucosal Protective Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Gastric Mucosal Protective Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Gastric Mucosal Protective Drugs manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Gastric Mucosal Protective Drugs by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Gastric Mucosal Protective Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Oral Medicines
- Injectable Medicines
Applications
- Child patients
- Elderly patients
- Youth patients
- Infant patients
Companies covered
- Abbott
- Takeda Pharmaceutical
- Taiho Pharmaceutical
- Sucralfate (Carafate)
- Pharmaking
- Misoprostol (Cytotec)
- Eisai
- Daewoong Pharmaceutical
- Cadila Healthcare
- Bismuth Subsalicylate (Pepto-Bismol)
- AstraZeneca
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Gastric Mucosal Protective Drugs Market Size (2021-2032)
- 2.2.2 Global Gastric Mucosal Protective Drugs Sales (2021-2032)
- 2.2.3 Global Gastric Mucosal Protective Drugs Market Average Price (2021-2032)
- 2.3 Gastric Mucosal Protective Drugs by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Oral Medicines
- 2.3.3 Injectable Medicines
- 2.4 Gastric Mucosal Protective Drugs by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Child patients
- 2.4.3 Elderly patients
- 2.4.4 Youth patients
- 2.4.5 Infant patients
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Gastric Mucosal Protective Drugs Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Gastric Mucosal Protective Drugs Sales (K Units) of Manufacturers (2021-2026)
- 3.3 Global Gastric Mucosal Protective Drugs Revenue of Manufacturers (2021-2026)
- 3.4 Global Gastric Mucosal Protective Drugs Average Price by Manufacturers (2021-2026)
- 3.5 Global Gastric Mucosal Protective Drugs Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Gastric Mucosal Protective Drugs, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Gastric Mucosal Protective Drugs, Product Type & Application
- 3.8 Global Manufacturers of Gastric Mucosal Protective Drugs, Established Date
- 3.9 Global Gastric Mucosal Protective Drugs Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Abbott
- 4.1.1 Abbott Company Information
- 4.1.2 Abbott Business Overview
- 4.1.3 Abbott Gastric Mucosal Protective Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Abbott Gastric Mucosal Protective Drugs Product Portfolio
- 4.1.5 Abbott Recent Developments
- 4.2 Takeda Pharmaceutical
- 4.2.1 Takeda Pharmaceutical Company Information
- 4.2.2 Takeda Pharmaceutical Business Overview
- 4.2.3 Takeda Pharmaceutical Gastric Mucosal Protective Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Takeda Pharmaceutical Gastric Mucosal Protective Drugs Product Portfolio
- 4.2.5 Takeda Pharmaceutical Recent Developments
- 4.3 Taiho Pharmaceutical
- 4.3.1 Taiho Pharmaceutical Company Information
- 4.3.2 Taiho Pharmaceutical Business Overview
- 4.3.3 Taiho Pharmaceutical Gastric Mucosal Protective Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Taiho Pharmaceutical Gastric Mucosal Protective Drugs Product Portfolio
- 4.3.5 Taiho Pharmaceutical Recent Developments
- 4.4 Sucralfate (Carafate)
- 4.4.1 Sucralfate (Carafate) Company Information
- 4.4.2 Sucralfate (Carafate) Business Overview
- 4.4.3 Sucralfate (Carafate) Gastric Mucosal Protective Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Sucralfate (Carafate) Gastric Mucosal Protective Drugs Product Portfolio
- 4.4.5 Sucralfate (Carafate) Recent Developments
- 4.5 Pharmaking
- 4.5.1 Pharmaking Company Information
- 4.5.2 Pharmaking Business Overview
- 4.5.3 Pharmaking Gastric Mucosal Protective Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Pharmaking Gastric Mucosal Protective Drugs Product Portfolio
- 4.5.5 Pharmaking Recent Developments
- 4.6 Misoprostol (Cytotec)
- 4.6.1 Misoprostol (Cytotec) Company Information
- 4.6.2 Misoprostol (Cytotec) Business Overview
- 4.6.3 Misoprostol (Cytotec) Gastric Mucosal Protective Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Misoprostol (Cytotec) Gastric Mucosal Protective Drugs Product Portfolio
- 4.6.5 Misoprostol (Cytotec) Recent Developments
- 4.7 Eisai
- 4.7.1 Eisai Company Information
- 4.7.2 Eisai Business Overview
- 4.7.3 Eisai Gastric Mucosal Protective Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Eisai Gastric Mucosal Protective Drugs Product Portfolio
- 4.7.5 Eisai Recent Developments
- 4.8 Daewoong Pharmaceutical
- 4.8.1 Daewoong Pharmaceutical Company Information
- 4.8.2 Daewoong Pharmaceutical Business Overview
- 4.8.3 Daewoong Pharmaceutical Gastric Mucosal Protective Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Daewoong Pharmaceutical Gastric Mucosal Protective Drugs Product Portfolio
- 4.8.5 Daewoong Pharmaceutical Recent Developments
- 4.9 Cadila Healthcare
- 4.9.1 Cadila Healthcare Company Information
- 4.9.2 Cadila Healthcare Business Overview
- 4.9.3 Cadila Healthcare Gastric Mucosal Protective Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Cadila Healthcare Gastric Mucosal Protective Drugs Product Portfolio
- 4.9.5 Cadila Healthcare Recent Developments
- 4.10 Bismuth Subsalicylate (Pepto-Bismol)
- 4.10.1 Bismuth Subsalicylate (Pepto-Bismol) Company Information
- 4.10.2 Bismuth Subsalicylate (Pepto-Bismol) Business Overview
- 4.10.3 Bismuth Subsalicylate (Pepto-Bismol) Gastric Mucosal Protective Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Bismuth Subsalicylate (Pepto-Bismol) Gastric Mucosal Protective Drugs Product Portfolio
- 4.10.5 Bismuth Subsalicylate (Pepto-Bismol) Recent Developments
- 4.11 AstraZeneca
- 4.11.1 AstraZeneca Company Information
- 4.11.2 AstraZeneca Business Overview
- 4.11.3 AstraZeneca Gastric Mucosal Protective Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 AstraZeneca Gastric Mucosal Protective Drugs Product Portfolio
- 4.11.5 AstraZeneca Recent Developments
5 Global Gastric Mucosal Protective Drugs Market Scenario by Region
- 5.1 Global Gastric Mucosal Protective Drugs Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Gastric Mucosal Protective Drugs Sales by Region: 2021-2032
- 5.2.1 Global Gastric Mucosal Protective Drugs Sales by Region: 2021-2026
- 5.2.2 Global Gastric Mucosal Protective Drugs Sales by Region: 2027-2032
- 5.3 Global Gastric Mucosal Protective Drugs Revenue by Region: 2021-2032
- 5.3.1 Global Gastric Mucosal Protective Drugs Revenue by Region: 2021-2026
- 5.3.2 Global Gastric Mucosal Protective Drugs Revenue by Region: 2027-2032
- 5.4 North America Gastric Mucosal Protective Drugs Market Facts & Figures by Country
- 5.4.1 North America Gastric Mucosal Protective Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Gastric Mucosal Protective Drugs Sales by Country (2021-2032)
- 5.4.3 North America Gastric Mucosal Protective Drugs Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Gastric Mucosal Protective Drugs Market Facts & Figures by Country
- 5.5.1 Europe Gastric Mucosal Protective Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Gastric Mucosal Protective Drugs Sales by Country (2021-2032)
- 5.5.3 Europe Gastric Mucosal Protective Drugs Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Gastric Mucosal Protective Drugs Market Facts & Figures by Country
- 5.6.1 Asia Pacific Gastric Mucosal Protective Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Gastric Mucosal Protective Drugs Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Gastric Mucosal Protective Drugs Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Gastric Mucosal Protective Drugs Market Facts & Figures by Country
- 5.7.1 South America Gastric Mucosal Protective Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Gastric Mucosal Protective Drugs Sales by Country (2021-2032)
- 5.7.3 South America Gastric Mucosal Protective Drugs Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.7.7 Colombia
- 5.8 Middle East and Africa Gastric Mucosal Protective Drugs Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Gastric Mucosal Protective Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Gastric Mucosal Protective Drugs Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Gastric Mucosal Protective Drugs Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Gastric Mucosal Protective Drugs Sales by Type (2021-2032)
- 6.1.1 Global Gastric Mucosal Protective Drugs Sales by Type (2021-2032) & (K Units)
- 6.1.2 Global Gastric Mucosal Protective Drugs Sales Market Share by Type (2021-2032)
- 6.2 Global Gastric Mucosal Protective Drugs Revenue by Type (2021-2032)
- 6.2.1 Global Gastric Mucosal Protective Drugs Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Gastric Mucosal Protective Drugs Revenue Market Share by Type (2021-2032)
- 6.3 Global Gastric Mucosal Protective Drugs Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Gastric Mucosal Protective Drugs Sales by Application (2021-2032)
- 7.1.1 Global Gastric Mucosal Protective Drugs Sales by Application (2021-2032) & (K Units)
- 7.1.2 Global Gastric Mucosal Protective Drugs Sales Market Share by Application (2021-2032)
- 7.2 Global Gastric Mucosal Protective Drugs Revenue by Application (2021-2032)
- 7.2.1 Global Gastric Mucosal Protective Drugs Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Gastric Mucosal Protective Drugs Revenue Market Share by Application (2021-2032)
- 7.3 Global Gastric Mucosal Protective Drugs Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Gastric Mucosal Protective Drugs Value Chain Analysis
- 8.1.1 Gastric Mucosal Protective Drugs Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Gastric Mucosal Protective Drugs Production Mode & Process
- 8.2 Gastric Mucosal Protective Drugs Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Gastric Mucosal Protective Drugs Distributors
- 8.2.3 Gastric Mucosal Protective Drugs Customers
9 Global Gastric Mucosal Protective Drugs Analyzing Market Dynamics
- 9.1 Gastric Mucosal Protective Drugs Industry Trends
- 9.2 Gastric Mucosal Protective Drugs Industry Drivers
- 9.3 Gastric Mucosal Protective Drugs Industry Opportunities and Challenges
- 9.4 Gastric Mucosal Protective Drugs Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst